Skip to main content
OpenTrials
Completed

NCT Number: NCT04565834

Effect of Genetic Alterations Affecting the Genes Encoding the Major Enzymes of the Kynurenine Pathway on Suicidal Behavior

Current research has shown that an imbalance in the Kynurenine pathway plays a role in the physiopathology of neurogenerative and mental disorders (with a decrease in neuroprotective metabolites and an increase in neurotoxic products). So far the research has concentrated on the enzymes IDO 1/2, KAT (1-4), KMO and ACMSD which are the key players in this pathway. Several polymorphisms affecting these enzymes have been associated with certain disorders characterized by a deregulation of the inflammation and immune response (McCauley et al 2009,Tardito et al 2013, Lee et al 2014), but the link between these enzymes and suicidal behavior is not yet clear. The investigators hypothesize that people with history of suicide attempt would have a genetic alterations of the kynurenine pathway specific for suicidal behavior.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Department of Psychiatry, Nimes University Hospital, Nîmes, Gard, France

Loading trial locations.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • For the "Sucide attempters" group: Any patient aged 18 or over who has made at least one suicide attempt.
  • For the two control groups: Any patient aged 18 or over, suffering from depression but has never attempted to commit suicide and any healthy subject who has never had any mental disorders.

Exclusion criteria

  • Any patient who has expressed opposition to the use of his/her data.

Treatment and study plan

SNP (single nucleotide polymorphism) genotyping

Genetic

We use TaqMan technique to perform SNP genotyping. The PCR reactions are carried out using the Roche "Light Cycler 480" thermal cycler following the protocol recommended by Thermo Fisher Scientific. Then, replication of 10% of the samples is carried out.

Other names: Determination of allelic and genotypic frequencies of IDO1 rs7820268, IDO2 rs10109853, KMO rs1053230, KAT1 rs10988134 and ACMSD rs2121337 SNPs in each group

Primary outcomes

  1. The genotypic and allelelic frequencies of IDO1 rs7820268 SNP in each studied group

    Time frame: 24 months

    The frequencies of this SNP will be measured as a percentage

  2. The genotypic and allelelic frequencies of IDO2 rs10109853 SNP in each studied group

    Time frame: 24 months

    The frequencies of this SNP will be measured as a percentage

  3. The genotypic and allelelic frequencies of KMO rs1053230 SNP in each studied group

    Time frame: 24 months

    The frequencies of this SNP will be measured as a percentage

  4. The genotypic and allelelic frequencies of KAT1 rs10988134 SNP in each studied group

    Time frame: 24 months

    The frequencies of this SNP will be measured as a percentage

  5. The genotypic and allelelic frequencies of ACMSD rs2121337 SNP in each studied group

    Time frame: 24 months

    The frequencies of this SNP will be measured as a percentage

Other outcomes

  1. Age of subjects

    Time frame: 24 months

    The age will be recorded for statistical purposes

  2. Gender of subjects

    Time frame: 24 months

    The gender will be recorded for statistical purposes

  3. Marital status of subjects

    Time frame: 24 months

    The marital status will be recorded as a number and a percentage

  4. Education level of subjects

    Time frame: 24 months

    the education level will be recorded as a number and a percentage

  5. Diagnosis

    Time frame: 24 months

    The diagnosis will be recorded as a number and a percentage

  6. Number of suicide attempts

    Time frame: 24 months

    The number of suicide attempts will be recorded as a number

  7. Age of first suicide attempt

    Time frame: 24 months

    Age of first suicide attempt will be recorded as a number

Sponsors and collaborators

Lead sponsor

Centre Hospitalier Universitaire de Nīmes

Other

Collaborators

  • Universidad Autonoma de Madrid

Registry information

Official study title

Étude Des Altérations Génétiques (polymorphismes) Des Gènes-clés De La Voie Kynurénine Sur Le Comportement Suicidaire

Acronym: SuiKYN

Important dates

Study start
2019
Primary completion
2023
Study completion
2023
First posted
Sep 25, 2020
Registry last updated
Feb 13, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.